MERIDIA

Compare MERIDIA  to:
Compare
Compare

Generic Name for MERIDIA

Sibutramine HCl monohydrate 5mg, 10mg, 15mg; caps.

Legal Classification:

CIV

Pharmacological Class for MERIDIA

Mixed neurotransmitter reuptake inhibitor.

Manufacturer of MERIDIA

Abbott Laboratories

Indications for MERIDIA

Adjunct to diet in the management of obesity in patients with initial body mass index ≥30kg/m2, or ≥27kg/m2 in presence of other risk factors.

Adult dose for MERIDIA

≥16years: Initially 10mg once daily. After 4 weeks, may titrate to 15mg once daily.

Children's dosing for MERIDIA

<16years: not recommended.

Contraindications for MERIDIA

History of coronary artery disease (eg, angina, MI), CHF, tachycardia, arrhythmias, cerebrovascular (eg, stroke, TIA) or peripheral arterial occlusive disease. Inadequately controlled hypertension >145/90mm Hg. Over 65 years of age. During or within 2 weeks of MAOIs (eg, phenelzine, selegiline) or concomitant centrally-acting appetite suppressants. Anorexia or bulimia nervosa.

Warnings/Precautions for MERIDIA

Exclude organic causes of obesity. Severe renal or hepatic dysfunction: not recommended. Do initial BP and pulse; monitor regularly during therapy; consider discontinuing or reducing dose for patients with sustained increases in either BP or pulse. Seizures (discontinue if occur). Hypertension. Narrow-angle glaucoma. Bleeding disorders. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.

Interactions for MERIDIA

See Contraindications. Avoid other serotonergic drugs (eg, SSRIs, venlafaxine); monitor if used together; possible serotonin syndrome with these and with sumatriptan, dihydroergotamine, some opioids (eg, dextromethorphan, meperidine, pentazocine, fentanyl), lithium, or tryptophan. Caution with other CNS-active drugs or drugs that can raise BP or pulse (eg, decongestants). Possible interaction with ketoconazole, erythromycin, others metabolized by CYP3A4. Excessive alcohol: not recommended. Caution with oral anticoagulants, platelet inhibitors.

Adverse Reactions for MERIDIA

Dry mouth, anorexia, insomnia, constipation, headache, increased appetite, dizziness, nervousness, GI upset, gallstones, increased BP and/or pulse, mydriasis, others.

How is MERIDIA supplied?

Caps—30

Related Disease:

Obesity

Related Resources

Solo Slim weight loss supplement recalled

August 09, 2010

EZVille and the FDA announced a recall of all lots of Solo Slim and Solo Slim Extra Strength capsules after FDA lab analyses showed the products to contain undeclared didesmethyl sibutramine.

FDA warns of dangerous ingredients in Joyful Slim herb supplement

July 22, 2010

The FDA is warning consumers that Joyful Slim herb supplement, marketed as a natural herb for weight loss, contains undeclared desmethyl sibutramine, an FDA-approved drug used as an appetite suppressant for weight loss.

FDA warns of dangerous ingredients in Slim-30 Herb Supplement

July 19, 2010

The FDA is warning consumers that Slim-30 Herb Supplement, an appetite suppressant for weight loss, contains undeclared N-Desmethyl sibutramine and traces of sibutramine.

FDA warns against Que She herbal supplement

July 08, 2010

The FDA has warned consumers and healthcare professionals that Que She, marketed as "Slimming Factor Capsule," an herbal weight loss supplement, contains undeclared ingredients that could harm consumers, especially those with cardiovascular conditions.

New data announced for Contrave for the treatment of obesity associated with type 2 diabetes

June 28, 2010

Orexigen announced data from its COR-Diabetes trial for Contrave (naltrexone sustained release (SR)/bupropion SR) for weight lowering and improved glycemic control in obese patients with type 2 diabetes.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions